EMCOR Group Inc (EME)vsWest Pharmaceutical Services Inc (WST)
EME
EMCOR Group Inc
$817.44
-3.31%
INDUSTRIALS · Cap: $36.65B
WST
West Pharmaceutical Services Inc
$314.50
-0.89%
HEALTHCARE · Cap: $23.23B
Smart Verdict
WallStSmart Research — data-driven comparison
EMCOR Group Inc generates 451% more annual revenue ($17.75B vs $3.22B). WST leads profitability with a 16.9% profit margin vs 7.5%. EME appears more attractively valued with a PEG of 0.44. EME earns a higher WallStSmart Score of 66/100 (B-).
EME
Strong Buy66
out of 100
Grade: B-
WST
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for EME.
Margin of Safety
-55.4%
Fair Value
$158.40
Current Price
$314.50
$156.10 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 35 in profit
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
19.7% revenue growth
Earnings expanding 30.0% YoY
Earnings expanding 56.1% YoY
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Strong operational efficiency at 21.7%
Revenue surging 21.0% year-over-year
Areas to Watch
Moderate valuation
Trading at 9.4x book value
7.5% margin — thin
Negative free cash flow — burning cash
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : EME
The strongest argument for EME centers on PEG Ratio, Return on Equity, Altman Z-Score. Revenue growth of 19.7% demonstrates continued momentum. PEG of 0.44 suggests the stock is reasonably priced for its growth.
Bull Case : WST
The strongest argument for WST centers on EPS Growth, Altman Z-Score, Debt/Equity. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.
Bear Case : EME
The primary concerns for EME are P/E Ratio, Price/Book, Profit Margin.
Bear Case : WST
The primary concerns for WST are PEG Ratio, P/E Ratio. A P/E of 44.1x leaves little room for execution misses.
Key Dynamics to Monitor
WST carries more volatility with a beta of 1.18 — expect wider price swings.
WST is growing revenue faster at 21.0% — sustainability is the question.
WST generates stronger free cash flow (47M), providing more financial flexibility.
Monitor ENGINEERING & CONSTRUCTION industry trends, competitive dynamics, and regulatory changes.
Bottom Line
EME scores higher overall (66/100 vs 65/100) and 19.7% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
EMCOR Group Inc
INDUSTRIALS · ENGINEERING & CONSTRUCTION · USA
EMCOR Group, Inc. provides electrical and mechanical installation and construction services in the United States. The company is headquartered in Norwalk, Connecticut.
West Pharmaceutical Services Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.
Compare with Other ENGINEERING & CONSTRUCTION Stocks
Want to dig deeper into these stocks?